AT’s comments make sense to all of us. It is the clinicians who need to agree to getting the patients twice or keep them overnight in the hospital. We have seen another ASX listed company where some of us are invested where clinicians saying and doing are two different things. FDA recognising the breakthrough/ accelerated approval is evidence enough for me but that needs to translate to deals meaning the licensor/ acquirer believes second day imaging will generate revenues.
IMHO, and I am sure some of you may disagree.
No advice.
Ann: Last patient assessment completed for SARTATE trial, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.11 |
Change
-0.200(4.64%) |
Mkt cap ! $1.329B | |||
| Open | High | Low | Value | Volume |
| $4.20 | $4.27 | $4.09 | $7.447M | 1.792M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $4.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.12 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |